Rivernorth Capital Management’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-652,432
| Closed | -$13.1K | – | 406 |
|
|
2025
Q1 | $13.1K | Hold |
652,432
| – | – | ﹤0.01% | 278 |
|
|
2024
Q4 | $65.2K | Hold |
652,432
| – | – | ﹤0.01% | 234 |
|
|
2024
Q3 | $46.1K | Hold |
652,432
| – | – | ﹤0.01% | 220 |
|
|
2024
Q2 | $65.2K | Hold |
652,432
| – | – | ﹤0.01% | 250 |
|
|
2024
Q1 | $78.3K | Sell |
652,432
-231
| -0% | -$26 | ﹤0.01% | 252 |
|
|
2023
Q4 | $52.2K | Hold |
652,663
| – | – | ﹤0.01% | 257 |
|
|
2023
Q3 | $255K | Hold |
652,663
| – | – | 0.01% | 262 |
|
|
2023
Q2 | $124K | Sell |
652,663
-162
| -0% | -$28 | 0.01% | 288 |
|
|
2023
Q1 | $91.4K | Hold |
652,825
| – | – | ﹤0.01% | 370 |
|
|
2022
Q4 | $52.2K | Buy |
652,825
+489,751
| +300% | +$41.1K | ﹤0.01% | 469 |
|
|
2022
Q3 | $24K | Buy |
163,074
+123,753
| +315% | +$21.3K | ﹤0.01% | 615 |
|
|
2022
Q2 | $10K | Hold |
39,321
| – | – | ﹤0.01% | 666 |
|
|
2022
Q1 | $24K | Sell |
39,321
-677
| -2% | -$563 | ﹤0.01% | 656 |
|
|
2021
Q4 | $46K | Hold |
39,998
| – | – | ﹤0.01% | 567 |
|
|
2021
Q3 | $46K | Buy |
+39,998
| New | +$50K | ﹤0.01% | 458 |
|
Rivernorth Capital Management's NKGNW Position: Q2 2025 in Review
Rivernorth Capital Management sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q2 2025, closing a stake of 652,432 shares — an estimated $13.1K sold.
Rivernorth Capital Management first reported a position in NKGNW in Q3 2021 and held it in 15 quarters. The position peaked at $255K in Q3 2023. 0 funds tracked by Wall St. Rank hold NKGNW as of Q2 2025.
- Rivernorth Capital Management reported no remaining NKGen Biotech, Inc. Warrants position as of Q2 2025 after selling out during the quarter.
- Rivernorth Capital Management sold 652,432 NKGen Biotech, Inc. Warrants shares in Q2 2025, an estimated $13.1K.
- Rivernorth Capital Management first reported a position in NKGen Biotech, Inc. Warrants in Q3 2021 and held it in 15 quarters.
- Rivernorth Capital Management's NKGen Biotech, Inc. Warrants position peaked at $255K in Q3 2023.
- 0 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q2 2025.
Based on Rivernorth Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.